;PMID: 10597262
;source_file_559.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:40..172] = [t:40..172]
;2)section:[e:176..261] = [t:176..261]
;3)section:[e:265..330] = [t:265..330]
;4)sentence:[e:334..589] = [t:334..589]
;5)sentence:[e:590..915] = [t:590..915]
;6)sentence:[e:916..1058] = [t:916..1058]
;7)sentence:[e:1059..1196] = [t:1059..1196]
;8)sentence:[e:1198..1281] = [t:1198..1281]
;9)sentence:[e:1282..1393] = [t:1282..1393]
;10)sentence:[e:1394..1464] = [t:1394..1464]
;11)sentence:[e:1465..1579] = [t:1465..1579]
;12)sentence:[e:1580..1741] = [t:1580..1741]
;13)sentence:[e:1742..1959] = [t:1742..1959]
;14)section:[e:1963..2008] = [t:1963..2008]

;section 0 Span:0..35
;Oncogene  1999 Nov 11;18(47):6583-8
(SEC
  (FRAG (RB:[0..8] Oncogene) (CD:[10..14] 1999) (.:[15..18] Nov)
        (CD:[19..23] 11;1) (CD:[23..24] 8) (-LRB-:[24..25] -LRB-)
        (CD:[25..27] 47) (-RRB-:[27..28] -RRB-) (::[28..29] :) (CD:[29..32] 658)
        (CD:[32..35] 3-8)))

;sentence 1 Span:40..172
;Close correlation between beta-catenin gene alterations and nuclear
;accumulation  of the protein in human hepatocellular carcinomas.
;[66..78]:gene-rna:"beta-catenin"
;[84..95]:variation-event:"alterations"
;[129..136]:gene-protein:"protein"
;[146..171]:malignancy:"hepatocellular carcinomas"
(SENT
  (NP-HLN
    (NP (JJ:[40..45] Close) (NN:[46..57] correlation))
    (PP (IN:[58..65] between)
      (NP
        (NP (NN:[66..78] beta-catenin) (NN:[79..83] gene)
            (NNS:[84..95] alterations))
        (CC:[96..99] and)
        (NP
          (NP (JJ:[100..107] nuclear) (NN:[108..120] accumulation))
          (PP (IN:[122..124] of)
            (NP (DT:[125..128] the) (NN:[129..136] protein))))))
    (PP-LOC (IN:[137..139] in)
      (NP (JJ:[140..145] human)
         (JJ:[146..160] hepatocellular) (NNS:[161..171] carcinomas)))
    (.:[171..172] .)))

;section 2 Span:176..261
;Terris B, Pineau P, Bregeaud L, Valla D, Belghiti J, Tiollais P, Degott C, 
;Dejean A.
(SEC
  (FRAG (NNP:[176..182] Terris) (NNP:[183..184] B) (,:[184..185] ,)
        (NNP:[186..192] Pineau) (NNP:[193..195] P,) (NNP:[196..204] Bregeaud)
        (NNP:[205..207] L,) (NNP:[208..213] Valla) (NNP:[214..215] D)
        (,:[215..216] ,) (NNP:[217..225] Belghiti) (NNP:[226..228] J,)
        (NNP:[229..237] Tiollais) (NNP:[238..240] P,) (NNP:[241..247] Degott)
        (NNP:[248..250] C,) (NNP:[252..258] Dejean) (NN:[259..261] A.)))

;section 3 Span:265..330
;Service d'Anatomie Pathologique, Hopital Beaujon, Clichy, France.
(SEC
  (FRAG (NNP:[265..272] Service) (NNP:[273..283] d'Anatomie)
        (NNP:[284..296] Pathologique) (,:[296..297] ,) (NNP:[298..305] Hopital)
        (NNP:[306..313] Beaujon) (,:[313..314] ,) (NNP:[315..321] Clichy)
        (,:[321..322] ,) (NNP:[323..329] France) (.:[329..330] .)))

;sentence 4 Span:334..589
;Several lines of evidence indicate that beta-catenin acquires oncogenic
;activity  when its intracellular concentration increases as a result of
;either mutation in  the beta-catenin gene itself or inactivation of the
;adenomatous polyposis coli  (APC) gene.
;[374..386]:gene-protein:"beta-catenin"
;[502..514]:gene-rna:"beta-catenin"
;[550..576]:gene-rna:"adenomatous polyposis coli"
;[579..582]:gene-rna:"APC"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[334..341] Several) (NNS:[342..347] lines))
      (PP (IN:[348..350] of)
        (NP (NN:[351..359] evidence))))
    (VP (VBP:[360..368] indicate)
      (SBAR (IN:[369..373] that)
        (S
          (NP-SBJ (NN:[374..386] beta-catenin))
          (VP (VBZ:[387..395] acquires)
            (NP (JJ:[396..405] oncogenic) (NN:[406..414] activity))
            (SBAR
              (WHADVP-1 (IN:[416..420] when))
              (S
                (NP-SBJ (PRP$:[421..424] its) (JJ:[425..438] intracellular)
                        (NN:[439..452] concentration))
                (VP (VBZ:[453..462] increases)
                  (PP (IN:[463..465] as)
                    (NP
                      (NP (DT:[466..467] a) (NN:[468..474] result))
                      (PP (IN:[475..477] of)
                        (NP (CC:[478..484] either)
                          (NP
                            (NP (NN:[485..493] mutation))
                            (PP-LOC (IN:[494..496] in)
                              (NP
                                (NP (DT:[498..501] the)
                                    (NN:[502..514] beta-catenin)
                                    (NN:[515..519] gene))
                                (NP (PRP:[520..526] itself)))))
                          (CC:[527..529] or)
                          (NP
                            (NP (NN:[530..542] inactivation))
                            (PP (IN:[543..545] of)
                              (NP (DT:[546..549] the)
                                (NML
                                  (NML (JJ:[550..561] adenomatous)
                                       (NN:[562..571] polyposis)
                                       (NN:[572..576] coli))
                                  (NML (-LRB-:[578..579] -LRB-)
                                       (NN:[579..582] APC)
                                       (-RRB-:[582..583] -RRB-)))
                                (NN:[584..588] gene))))))))
                  (ADVP-TMP-1 (-NONE-:[588..588] *T*)))))))))
    (.:[588..589] .)))

;sentence 5 Span:590..915
;In an attempt to elucidate the molecular mechanisms underlying 
;hepatocellular carcinogenesis, we have studied the frequency of beta-catenin 
;gene alterations in exon 3, a region known to represent a mutation hot spot,
;and  its inappropriate protein expression by immunohistochemistry in 73 
;hepatocellular carcinomas (HCCs).
;[718..730]:gene-rna:"beta-catenin"
;[737..748]:variation-event:"alterations"
;[752..758]:variation-location:"exon 3"
;[832..839]:gene-protein:"protein"
;[882..907]:malignancy:"hepatocellular carcinomas"
;[909..913]:malignancy:"HCCs"
(SENT
  (S
    (PP (IN:[590..592] In)
      (NP (DT:[593..595] an) (NN:[596..603] attempt)
        (S
          (NP-SBJ (-NONE-:[603..603] *))
          (VP (TO:[604..606] to)
            (VP (VB:[607..616] elucidate)
              (NP
                (NP (DT:[617..620] the) (JJ:[621..630] molecular)
                    (NNS:[631..641] mechanisms))
                (VP (VBG:[642..652] underlying)
                  (NP (JJ:[654..668] hepatocellular)
                      (NN:[669..683] carcinogenesis)))))))))
    (,:[683..684] ,)
    (NP-SBJ (PRP:[685..687] we))
    (VP (VBP:[688..692] have)
      (VP (VBN:[693..700] studied)
        (NP
          (NP
            (NP (DT:[701..704] the) (NN:[705..714] frequency))
            (PP (IN:[715..717] of)
              (NP
                (NP (NN:[718..730] beta-catenin) (NN:[732..736] gene)
                    (NNS:[737..748] alterations))
                (PP-LOC (IN:[749..751] in)
                  (NP
                    (NP (NN:[752..756] exon) (CD:[757..758] 3))
                    (,:[758..759] ,)
                    (NP
                      (NP (DT:[760..761] a) (NN:[762..768] region))
                      (VP (VBN:[769..774] known)
                        (S
                          (NP-SBJ (-NONE-:[774..774] *))
                          (VP (TO:[775..777] to)
                            (VP (VB:[778..787] represent)
                              (NP (DT:[788..789] a) (NN:[790..798] mutation)
                                  (JJ:[799..802] hot) (NN:[803..807] spot))))))))))))
          (,:[807..808] ,) (CC:[809..812] and)
          (NP (PRP$:[814..817] its) (JJ:[818..831] inappropriate)
              (NN:[832..839] protein) (NN:[840..850] expression)))
        (PP-MNR (IN:[851..853] by)
          (NP (NN:[854..874] immunohistochemistry)))
        (PP-LOC (IN:[875..877] in)
          (NP (CD:[878..880] 73)
            (NML
              (NML (JJ:[882..896] hepatocellular) (NNS:[897..907] carcinomas))
              (NML (-LRB-:[908..909] -LRB-) (NNS:[909..913] HCCs)
                   (-RRB-:[913..914] -RRB-)))))))
    (.:[914..915] .)))

;sentence 6 Span:916..1058
;The results were correlated with different  clinical and pathological data,
;particularly with the presence or not of an  associated cirrhosis.
(SENT
  (S
    (NP-SBJ-1 (DT:[916..919] The) (NNS:[920..927] results))
    (VP (VBD:[928..932] were)
      (VP (VBN:[933..943] correlated)
        (NP-1 (-NONE-:[943..943] *))
        (PP-CLR (IN:[944..948] with)
          (NP (JJ:[949..958] different)
            (ADJP (JJ:[960..968] clinical) (CC:[969..972] and)
                  (JJ:[973..985] pathological))
            (NNS:[986..990] data)))
        (,:[990..991] ,)
        (PP
          (ADVP (RB:[992..1004] particularly))
          (IN:[1005..1009] with)
          (NP
            (NP
              (NP (DT:[1010..1013] the) (NN:[1014..1022] presence))
              (FRAG (CC:[1023..1025] or) (RB:[1026..1029] not)))
            (PP (IN:[1030..1032] of)
              (NP (DT:[1033..1035] an) (JJ:[1037..1047] associated)
                  (NN:[1048..1057] cirrhosis)))))))
    (.:[1057..1058] .)))

;sentence 7 Span:1059..1196
;Fourteen (19%) HCCs showed beta-catenin gene alterations  with missense
;mutations in nine cases and interstitial deletions in five cases.
;[1074..1078]:malignancy:"HCCs"
;[1086..1098]:gene-rna:"beta-catenin"
;[1104..1115]:variation-event:"alterations"
;[1122..1140]:variation-type:"missense mutations"
;[1159..1181]:variation-type:"interstitial deletions"
(SENT
  (S
    (NP-SBJ (CD:[1059..1067] Fourteen)
      (PRN (-LRB-:[1068..1069] -LRB-)
        (NP (CD:[1069..1071] 19) (NN:[1071..1072] %))
        (-RRB-:[1072..1073] -RRB-))
      (NNS:[1074..1078] HCCs))
    (VP (VBD:[1079..1085] showed)
      (NP (NN:[1086..1098] beta-catenin) (NN:[1099..1103] gene)
          (NNS:[1104..1115] alterations))
      (PP (IN:[1117..1121] with)
        (NP
          (NP
            (NP (JJ:[1122..1130] missense) (NNS:[1131..1140] mutations))
            (PP (IN:[1141..1143] in)
              (NP (CD:[1144..1148] nine) (NNS:[1149..1154] cases))))
          (CC:[1155..1158] and)
          (NP
            (NP (JJ:[1159..1171] interstitial) (NNS:[1172..1181] deletions))
            (PP (IN:[1182..1184] in)
              (NP (CD:[1185..1189] five) (NNS:[1190..1195] cases)))))))
    (.:[1195..1196] .)))

;sentence 8 Span:1198..1281
;These genetic alterations were present in both cirrhotic and non-cirrhotic 
;groups.
;[1204..1223]:variation-event:"genetic alterations"
(SENT
  (S
    (NP-SBJ (DT:[1198..1203] These)
       (JJ:[1204..1211] genetic) (NNS:[1212..1223] alterations))
    (VP (VBD:[1224..1228] were)
      (ADJP-PRD (JJ:[1229..1236] present))
      (PP (IN:[1237..1239] in)
        (NP (DT:[1240..1244] both)
          (NP (JJ:[1245..1254] cirrhotic)
            (NML-1 (-NONE-:[1254..1254] *P*)))
          (CC:[1255..1258] and)
          (NP
            (ADJP (AFX:[1259..1262] non) (HYPH:[1262..1263] -)
                  (JJ:[1263..1272] cirrhotic))
            (NML-1 (NNS:[1274..1280] groups))))))
    (.:[1280..1281] .)))

;sentence 9 Span:1282..1393
;By contrast, we did not find any beta-catenin gene alterations in the  nine
;fibromellar carcinomas we examined.
;[1315..1327]:gene-rna:"beta-catenin"
;[1358..1380]:malignancy:"fibromellar carcinomas"
(SENT
  (S
    (PP (IN:[1282..1284] By)
      (NP (NN:[1285..1293] contrast)))
    (,:[1293..1294] ,)
    (NP-SBJ (PRP:[1295..1297] we))
    (VP (VBD:[1298..1301] did) (RB:[1302..1305] not)
      (NP (VB:[1306..1310] find)
        (NP (DT:[1311..1314] any) (NN:[1315..1327] beta-catenin)
            (NN:[1328..1332] gene) (NNS:[1333..1344] alterations))
        (PP (IN:[1345..1347] in)
          (NP
            (NP (DT:[1348..1351] the) (CD:[1353..1357] nine)
               (JJ:[1358..1369] fibromellar) (NNS:[1370..1380] carcinomas))
            (SBAR
              (WHNP-1 (-NONE-:[1380..1380] 0))
              (S
                (NP-SBJ (PRP:[1381..1383] we))
                (VP (VBD:[1384..1392] examined)
                  (NP-1 (-NONE-:[1392..1392] *T*)))))))))
    (.:[1392..1393] .)))

;sentence 10 Span:1394..1464
;Nuclear accumulation of the protein was  observed in 18 of them (25%).
;[1422..1429]:gene-protein:"protein"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[1394..1401] Nuclear) (NN:[1402..1414] accumulation))
      (PP (IN:[1415..1417] of)
        (NP (DT:[1418..1421] the) (NN:[1422..1429] protein))))
    (VP (VBD:[1430..1433] was)
      (VP (VBN:[1435..1443] observed)
        (NP-1 (-NONE-:[1443..1443] *))
        (PP (IN:[1444..1446] in)
          (NP
            (NP (CD:[1447..1449] 18))
            (PP (IN:[1450..1452] of)
              (NP (PRP:[1453..1457] them)))
            (PRN (-LRB-:[1458..1459] -LRB-)
              (NP (CD:[1459..1461] 25) (NN:[1461..1462] %))
              (-RRB-:[1462..1463] -RRB-))))))
    (.:[1463..1464] .)))

;sentence 11 Span:1465..1579
;Remarkably, these included ten of the 14 tumors  harboring somatic mutations
;in the beta-catenin gene (P < 0.001).
;[1506..1512]:malignancy:"tumors"
;[1549..1561]:gene-rna:"beta-catenin"
(SENT
  (S
    (ADVP (RB:[1465..1475] Remarkably))
    (,:[1475..1476] ,)
    (NP-SBJ (DT:[1477..1482] these))
    (VP (VBD:[1483..1491] included)
      (NP
        (NP (CD:[1492..1495] ten))
        (PP (IN:[1496..1498] of)
          (NP
            (NP (DT:[1499..1502] the) (CD:[1503..1505] 14)
                (NNS:[1506..1512] tumors))
            (VP (VBG:[1514..1523] harboring)
              (NP (JJ:[1524..1531] somatic) (NNS:[1532..1541] mutations))
              (PP-LOC (IN:[1542..1544] in)
                (NP (DT:[1545..1548] the) (NN:[1549..1561] beta-catenin)
                    (NN:[1562..1566] gene)))))))
      (PRN (-LRB-:[1567..1568] -LRB-)
        (S
          (NP-SBJ (NN:[1568..1569] P))
          (VP (SYM:[1570..1571] <)
            (NP (CD:[1572..1577] 0.001))))
        (-RRB-:[1577..1578] -RRB-)))
    (.:[1578..1579] .)))

;sentence 12 Span:1580..1741
;Our results  indicate that accumulation of beta-catenin resulting from
;genetic mutations is a  frequent event in non-fibrolamellar type
;hepatocellular carcinoma.
;[1623..1635]:gene-protein:"beta-catenin"
;[1659..1668]:variation-event:"mutations"
;[1693..1740]:malignancy:"non-fibrolamellar type hepatocellular carcinoma"
(SENT
  (S
    (NP-SBJ (PRP$:[1580..1583] Our) (NNS:[1584..1591] results))
    (VP (VBP:[1593..1601] indicate)
      (SBAR (IN:[1602..1606] that)
        (S
          (NP-SBJ
            (NP
              (NP (NN:[1607..1619] accumulation))
              (PP (IN:[1620..1622] of)
                (NP (NN:[1623..1635] beta-catenin))))
            (VP (VBG:[1636..1645] resulting)
              (PP (IN:[1646..1650] from)
                (NP (JJ:[1651..1658] genetic) (NNS:[1659..1668] mutations)))))
          (VP (VBZ:[1669..1671] is)
            (NP-PRD (DT:[1672..1673] a) (JJ:[1675..1683] frequent)
                    (NN:[1684..1689] event))
            (PP (IN:[1690..1692] in)
              (NP
                (NML
                  (ADJP (AFX:[1693..1696] non) (HYPH:[1696..1697] -)
                        (JJ:[1697..1710] fibrolamellar))
                  (NN:[1711..1715] type))
                (JJ:[1716..1730] hepatocellular) (NN:[1731..1740] carcinoma)))))))
    (.:[1740..1741] .)))

;sentence 13 Span:1742..1959
;The close  association between increased beta-catenin protein stability and
;mutation  indicates that immunohistochemistry may be a powerful method for
;the detection  of the mutated protein in future clinical practice.
;[1783..1795]:gene-protein:"beta-catenin"
;[1818..1826]:variation-event:"mutation"
;[1923..1930]:gene-protein:"protein"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1742..1745] The) (JJ:[1746..1751] close)
          (NN:[1753..1764] association))
      (PP (IN:[1765..1772] between)
        (NP
          (NP (JJ:[1773..1782] increased) (NN:[1783..1795] beta-catenin)
              (NN:[1796..1803] protein) (NN:[1804..1813] stability))
          (CC:[1814..1817] and)
          (NP (NN:[1818..1826] mutation)))))
    (VP (VBZ:[1828..1837] indicates)
      (SBAR (IN:[1838..1842] that)
        (S
          (NP-SBJ (NN:[1843..1863] immunohistochemistry))
          (VP (MD:[1864..1867] may)
            (VP (VB:[1868..1870] be)
              (NP-PRD
                (NP (DT:[1871..1872] a) (JJ:[1873..1881] powerful)
                    (NN:[1882..1888] method))
                (PP (IN:[1889..1892] for)
                  (NP
                    (NP (DT:[1893..1896] the) (NN:[1897..1906] detection))
                    (PP (IN:[1908..1910] of)
                      (NP (DT:[1911..1914] the) (JJ:[1915..1922] mutated)
                          (NN:[1923..1930] protein))))))
              (PP (IN:[1931..1933] in)
                (NP (JJ:[1934..1940] future) (JJ:[1941..1949] clinical)
                    (NN:[1950..1958] practice))))))))
    (.:[1958..1959] .)))

;section 14 Span:1963..2008
;PMID: 10597262 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1963..1967] PMID) (::[1967..1968] :) (CD:[1969..1977] 10597262)
        (NN:[1978..1979] -LSB-) (NNP:[1979..1985] PubMed) (::[1986..1987] -)
        (NN:[1988..1995] indexed) (IN:[1996..1999] for)
        (NNP:[2000..2008] MEDLINE-RSB-)))
